Upcoming events – Phase III data for Chiasma and Novartis
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Price fixing case caps a terrible week for generics
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Novartis sees hidden value in Xiidra
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
AAN 2019 – Roche confirms its place in spinal muscular atrophy
A slew of data on spinal muscular atrophy projects over the weekend shows that this tiny market is set for some big competition, with Novartis, Roche and Biogen jostling…
Faint hope for Alder as Teva bucks dismal migraine trend
Alder hopes soon to launch its migraine drug eptinezumab, and will nervously have been watching the first full quarter’s sales of three similarly acting drugs.
Deciphera nears its biggest test
The small-molecule oncology player zeroes in on its first commercial opportunity.
Looking back at April’s data digging and analysis
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
Upcoming events – crucial cancer data for Tocagen and Syndax
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.
Astra’s first attempt fails, but there’s no giving up on KRAS
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.